Overview

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

Status:
Withdrawn
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.
Phase:
Phase 4
Details
Lead Sponsor:
Jewish General Hospital
Treatments:
Pharmaceutical Solutions
Treprostinil